IL297640A - Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies - Google Patents

Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies

Info

Publication number
IL297640A
IL297640A IL297640A IL29764022A IL297640A IL 297640 A IL297640 A IL 297640A IL 297640 A IL297640 A IL 297640A IL 29764022 A IL29764022 A IL 29764022A IL 297640 A IL297640 A IL 297640A
Authority
IL
Israel
Prior art keywords
antigen
antibody
binding fragment
ctla
dose
Prior art date
Application number
IL297640A
Other languages
English (en)
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL297640A publication Critical patent/IL297640A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL297640A 2020-05-12 2021-05-12 Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies IL297640A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063023554P 2020-05-12 2020-05-12
PCT/EP2021/062695 WO2021228978A1 (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Publications (1)

Publication Number Publication Date
IL297640A true IL297640A (en) 2022-12-01

Family

ID=75977756

Family Applications (2)

Application Number Title Priority Date Filing Date
IL297640A IL297640A (en) 2020-05-12 2021-05-12 Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies
IL311936A IL311936A (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL311936A IL311936A (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Country Status (12)

Country Link
US (3) US20220363762A1 (enExample)
EP (1) EP4021940A1 (enExample)
JP (2) JP7387912B2 (enExample)
KR (1) KR20230009354A (enExample)
CN (1) CN114729054A (enExample)
AU (3) AU2021269832B2 (enExample)
BR (1) BR112022021893A2 (enExample)
CA (1) CA3158607A1 (enExample)
IL (2) IL297640A (enExample)
MX (1) MX2022006728A (enExample)
TW (2) TW202535468A (enExample)
WO (1) WO2021228978A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054897A1 (en) * 2022-09-07 2024-03-14 The University Of Chicago Methods for treating cancer with hyperactive adar enzymes
WO2025211692A1 (ko) * 2024-04-02 2025-10-09 (주)에트노바테라퓨틱스 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
AU2003234090A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
AU2003247337B2 (en) 2002-04-11 2007-09-06 Medimmune, Llc Preservation of bioactive materials by freeze dried foam
KR20050011741A (ko) 2002-04-11 2005-01-29 메드이뮨 백신즈 인코포레이티드 분무 건조에 의한 생물학적 활성 물질의 보존
CA2508592A1 (en) 2002-12-17 2004-07-15 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
EP3206711B1 (en) * 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
HK1247578A1 (zh) * 2015-04-01 2018-09-28 Medimmune Limited 用於治疗非小细胞肺癌的组合抗pd-l1和抗ctla4抗体
EP3472207B1 (en) * 2016-06-20 2021-01-20 F-Star Delta Limited Binding molecules binding pd-l1 and lag-3
WO2018064013A1 (en) * 2016-09-27 2018-04-05 Peregrine Pharmaceuticals, Inc. METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
WO2018187227A1 (en) * 2017-04-03 2018-10-11 Concologie, Inc. Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
CA3064829C (en) * 2017-05-26 2023-08-22 Bruin Biosciences, Inc. Chemoembolization agents
KR20200016899A (ko) * 2017-06-01 2020-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항-pdl1 항체, 및 이의 이용 방법
US20210260051A1 (en) * 2018-06-14 2021-08-26 Board Of Regents, The University Of Texas System Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
JP2021527651A (ja) * 2018-06-15 2021-10-14 ミナ セラピューティクス リミテッド Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法

Also Published As

Publication number Publication date
JP2023524359A (ja) 2023-06-12
CA3158607A1 (en) 2021-11-18
AU2024266949A1 (en) 2024-12-19
IL311936A (en) 2024-06-01
WO2021228978A1 (en) 2021-11-18
JP2024016209A (ja) 2024-02-06
BR112022021893A2 (pt) 2022-12-20
US20210355224A1 (en) 2021-11-18
AU2021269832A1 (en) 2022-05-19
TW202535468A (zh) 2025-09-16
EP4021940A1 (en) 2022-07-06
AU2021269832B2 (en) 2024-09-19
AU2024202963A1 (en) 2024-05-30
MX2022006728A (es) 2022-06-09
TWI870592B (zh) 2025-01-21
TW202207976A (zh) 2022-03-01
KR20230009354A (ko) 2023-01-17
CN114729054A (zh) 2022-07-08
JP7387912B2 (ja) 2023-11-28
AU2024202963B2 (en) 2025-11-20
US20240239893A1 (en) 2024-07-18
US20220363762A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
IL276481A (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
IL274462A (en) Anti-b7-h1 antibodies for treating tumors
JP6499971B2 (ja) 抗ｃｄ３８抗体及びレナリドマイドを含む組成物
IL297884A (en) Triple combination therapy to increase cancer cell killing in cancers with low immunogenicity
IL247102B2 (en) Combination of pd-1 antagonist and ido1 inhibitor for cancer treatment
IL272321B1 (en) Methods and compositions for treating amyloid deposition diseases
IL311399A (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
IL298438A (en) Therapeutic combinations comprising anti-folr1 immunoconjugates
IL302133A (en) A combination of a rexinoid and retinoid substance with immunomodulatory properties and immunomodulatory substances for cancer treatment
AU2024202963B2 (en) Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies
IL298044A (en) Anti-folr1 immunoconjugate dosing regimens
IL241407B (en) Compositions comprising anti-cd38 antibodies and carfilzomib
IL278522B1 (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
CN120053637A (zh) 抗dll3药剂的给药方案
IL295372A (en) Methods for treating connective tissue sclerosis and related conditions
IL302346A (en) Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
IL297043A (en) Drug combination including tno155 and nazaretinib
IL298155A (en) Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
CN113164600A (zh) 转移性胰脏腺癌的治疗
IL311497A (en) Use of an antibody-drug conjugate, and a combined drug and its use
IL300415A (en) Methods for treating multiple sclerosis with ocralizumab
US20240317854A1 (en) Methods for treating cancer with anti-ilt3 antibodies
IL295202A (en) Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
IL311495A (en) Antibody drug conjugate formulation and use thereof
IL300975A (en) Methods of treating cancer pain by administering a pd-1 inhibitor